Stock News

USW Local 7619 represents about 1,200 workers at the B.C. copper operation, whose production loss has not been quantified.

A US$1.2 billion agreement spans 2026 to 2030, while a one-time tariff refund lifted the September quarter’s reported earnings.

Proprietary bitcoin holdings remained at zero as of Oct. 23, while the update omitted sale prices and cash proceeds.

The California services acquisition would close in two stages, with cash, a seller note and an earnout subject to separate utility approvals.

New applications came in below a 200,000 forecast, while continuing claims increased by 25,000 in the Labor Department's weekly report.

The upper Hotspot results will inform geological modelling, with true widths still unestablished and some holes cut short by ground conditions.

Crews are assessing two undrilled occurrences and the corridor between them, with initial results expected in early 2027.

An independent board will review ReMEDy2 in Q1 2027 and may resize the study to as many as 728 participants or stop it for futility.

Rigs are secured for approved drilling at Aberfoyle and Great Pyramid, while separate tailings work awaits regulatory approval.

The hepatitis B developer can pursue further United States testing, but has not disclosed a new trial design or start date.

The developer will stop internal Rejuva gene-therapy work and forecasts cash into Q2 2027, ahead of a potential 2028 launch.

The interval also returned 0.83 per cent antimony, but true widths remain unknown after the completed 14-hole campaign.

A 131-patient registry analysis found higher graft risk, while a separate randomized trial reported 49% fewer kidney biopsies.

A 1,859-patient pivotal trial will compare the resorbable implant with Xience, with primary completion estimated for June 2029.

The estimate uses a higher value cutoff and revised metal prices ahead of a fourth-quarter economic study of the New Mexico project.

The annual profit outlook is unchanged, while higher working capital needs and restructuring reduce expected cash conversion.

The first hole supports continuity within the resource footprint, but true widths remain unknown and assays from 10 holes are pending.

The 24-week injection course targets eligible adults without cirrhosis, with boxed liver and platelet warnings.

The benefit expense ratio improved to 90.6 per cent, but non-operating gains helped lift earnings and the annual forecast.

The indication covers severe symptomatic leakage despite medical therapy, with pivotal one-year findings due at TCT.

Holders would receive C$0.084 cash and 0.0763 QeM shares per share, with former Plurilock owners projected to hold 4.03 per cent after closing.

Hudbay expects to contribute about US$500 million from 2028, with first production at the Arizona mine targeted for the second half of 2029.

Confirmed disability progression affected 11.7 per cent with continuous treatment versus 17.4 per cent after an initial comparator.

Banking and auto indexes fell while Infosys prepares to release its September quarter results on Oct. 23.

The company reports true widths and plans electromagnetic surveying before drilling the lens along strike and at depth.

Alaska Railroad is the recipient, with US$62 million in state and local contributions toward the Port MacKenzie extension.

The higher-grade oxide zone lies about 50 metres below the pit design, with a resource update expected in the second quarter of 2027.

Patients aged 12 and older gain an alternative to capsules, while the approval release gives no launch date for the new strength.

The pre-feasibility study estimates C$127M in initial capital, with commercial production planned for early 2030.

ReElement reports high-purity oxide; the Oct. 21 release gives no assay percentage, test volume or schedule for the U.S. demonstration.

Preliminary gross margin of 12 to 12.5 per cent tops prior guidance, with final September-quarter results due Nov. 3.

The capsules are intended for three programs, including a Canadian Phase 3 PTSD trial of up to 100 people expected to begin in 2027.

The placebo-controlled study tests two doses of NBI-'567 over 12 weeks, with primary completion estimated for May 2028.

The Oct. 20 release describes 4.47 EH/s of operating equipment but gives no current share count for calculating percentage dilution.